First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results

PUPs A-LONG evaluated the safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in previously untreated patients (PUPs) with hemophilia A. This open-label, phase 3 study enrolled male PUPs (<6 years) with severe hemophilia A to receive rFVIIIFc. The primary endpoint was the...

Descripción completa

Detalles Bibliográficos
Autores principales: Königs, Christoph, Ozelo, Margareth C., Dunn, Amy, Kulkarni, Roshni, Nolan, Beatrice, Brown, Simon A., Schiavulli, Michele, Gunawardena, Sriya, Mukhopadhyay, Sutirtha, Jayawardene, Deepthi, Winding, Bent, Carcao, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642851/
https://www.ncbi.nlm.nih.gov/pubmed/35421219
http://dx.doi.org/10.1182/blood.2021013563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642851/
https://www.ncbi.nlm.nih.gov/pubmed/35421219
http://dx.doi.org/10.1182/blood.2021013563

Ejemplares similares